Extended Data Fig. 10: Graphic illustration showing the design of the current study.
From: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
![Extended Data Fig. 10](https://cdn.statically.io/img/media.springernature.com/full/springer-static/esm/art%3A10.1038%2Fs41586-024-07121-9/MediaObjects/41586_2024_7121_Fig16_ESM.jpg)
Top, To understand the mechanism(s) of response with tiragolumab in combination with atezolizumab, we leveraged samples collected from CITYSCAPE (left; NSCLC, Ph2) including tumour pretreatment samples for bulk RNA-seq and multiplex immunofluorescence (mIF), and pretreatment and on-treatment serum samples for Mass Spec, GO30103 (middle; NSCLC, Ph1b) including pretreatment and on-treatment peripheral blood mononuclear cells (PMBC) for single cell RNA-seq, and preclinical models (right). Bottom, Anti-TIGIT antibody, in a Fc dependent manner, remodels immunosuppressive tumour microenvironments by leveraging myeloid cells and Tregs, which was further enhanced with the addition of anti-PD-(L)1 antibody. Created with BioRender.com.